PGEN Stock - Precigen, Inc.
Unlock GoAI Insights for PGEN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.92M | $6.22M | $26.91M | $14.27M | $31.99M |
| Gross Profit | $-342,000 | $106,000 | $20.57M | $-39,411,000 | $-12,810,000 |
| Gross Margin | -8.7% | 1.7% | 76.4% | -276.2% | -40.0% |
| Operating Income | $-135,029,000 | $-99,758,000 | $-75,726,000 | $-91,948,000 | $-86,318,000 |
| Net Income | $-126,235,000 | $-95,904,000 | $28.32M | $-92,166,000 | $-170,521,000 |
| Net Margin | -3216.2% | -1540.6% | 105.2% | -646.0% | -533.0% |
| EPS | $-0.47 | $-0.39 | $-0.33 | $-0.47 | $-1.02 |
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 15th 2025 | JP Morgan | Upgrade | Neutral | - |
| March 22nd 2024 | JP Morgan | Downgrade | Underweight | - |
| May 23rd 2023 | JP Morgan | Initiation | Neutral | - |
| November 18th 2022 | Cantor Fitzgerald | Initiation | Overweight | $7 |
Earnings History & Surprises
PGENEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 18, 2026 | $-0.10 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.08 | $-0.11 | -37.5% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.14 | $-0.11 | +21.4% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.08 | $-0.07 | +12.5% | ✓ BEAT |
Q1 2025 | Mar 19, 2025 | $-0.06 | $-0.04 | +33.3% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.08 | $-0.09 | -12.5% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.09 | $-0.10 | -11.1% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.09 | $-0.10 | -11.1% | ✗ MISS |
Q1 2024 | Feb 13, 2024 | $-0.08 | $-0.13 | -62.5% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.08 | $-0.08 | 0.0% | = MET |
Q3 2023 | Aug 9, 2023 | $-0.10 | $-0.08 | +20.0% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-0.08 | $-0.10 | -25.0% | ✗ MISS |
Q1 2023 | Mar 6, 2023 | $-0.10 | $-0.11 | -10.0% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $0.10 | $-0.04 | -140.0% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-0.16 | $-0.13 | +18.8% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.14 | $-0.10 | +28.6% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-0.14 | $-0.13 | +7.1% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-0.14 | $-0.15 | -7.1% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | — | $-0.01 | — | — |
Latest News
Vaxart, Precigen among biotech gainers after Q3 results
📈 PositiveHC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $9
📈 PositivePrecigen Q3 EPS $(1.06) Misses $(0.10) Estimate, Sales $2.922M Beat $500.000K Estimate
➖ NeutralPrecigen Reports Responses to PAPZIMEOS in Adults With Recurrent Respiratory Papillomatosis, Reinforcing FDA Approval
📈 PositivePrecigen Entered Into A Credit Facility Agreement With Pharmakon Advisors For Up $125M In Non-Dilutive Funding
📈 PositivePrecigen shares are trading higher after JMP Securities raised its price target on the stock from $6 to $8.
📈 PositiveJMP Securities Maintains Market Outperform on Precigen, Raises Price Target to $8
📈 PositiveHC Wainwright & Co. Reiterates Buy on Precigen, Maintains $8.5 Price Target
📈 PositivePrecigen surges on FDA approval for gene therapy
📈 PositiveFrequently Asked Questions about PGEN
What is PGEN's current stock price?
What is the analyst price target for PGEN?
What sector is Precigen, Inc. in?
What is PGEN's market cap?
Does PGEN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PGEN for comparison